Georgetown University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Georgetown University sits in the top decile of US sponsors by registered trial count (#144 of 15,742 sponsors by registered trial count).
Georgetown University: 227 sponsored US clinical trials, 34 recruiting.
Georgetown University sponsors 227 registered US clinical trials on ClinicalTrials.gov, 34 of them currently recruiting, and 130 completed. 27 of these trials are in Phase 3-4 (later-stage) and 98 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 5 trials.
Top-decile sponsor footprint
Georgetown University ranks in the top decile of sponsors by registered trial count (#144 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
130 of 174 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (74.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
227 total, page 4 of 5
Lapatinib and Bortezomib in Patients With Advanced Malignancies
NCT01497626
Oxidative Stress in Obstructive Sleep Apnea: Correlation of Biomarkers and Nasal CPAP Compliance
NCT01661699
Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)
NCT01356147
Determination of the Pathophysicologic Collagen Changes in the Diabetic Achilles Tendon
NCT01382628
Diagnostic Tests to Help Determine Osteomyelitis
NCT01612962
Endoscopic Evaluation of Late Rectal Injury Following CyberKnife Radiosurgery for Prostate Cancer
NCT01618838
ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
NCT01489865
Biomarkers Serum Collection Methodology Pilot Study
NCT01318707
Reader Study of DeltaView™ Chest Radiograph Software
NCT01261507
The PRIDE Study Probiotics on Regulation and Improving Digestive hEalth
NCT01203462
Text-Messaging to Motivate Walking in Older African Americans
NCT01697475
A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
NCT01322815
ABT-888 and Temozolomide for Liver Cancer
NCT01205828
Breast Health in Chinese American Women
NCT01292200
A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
NCT01050985
Lapatinib and Cetuximab in Patients With Solid Tumors
NCT01184482
Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers
NCT01108263
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)
NCT01010568
A Study of Gemcitabine and Cyberknife Radiation Therapy for Pancreatic Cancer
NCT01051284
Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Adults on Antibiotics
NCT00848003
Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients
NCT00998426
A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
NCT01051596
Albumin for Intracerebral Hemorrhage Intervention
NCT00990509
Sunitinib and Capecitabine for First Line Colon Cancer
NCT00961571
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
NCT00881621
Exercise in Gulf War Illness (GWI)
NCT01291758
A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma
NCT00881504
Testing of Computer Aided Detection Software for Riverain Medical Group
NCT00906789
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
NCT00864942
Impact of Two Methods of Listening to Music During Exercise on Perceived Exertion and Overall Physical Activity
NCT00804700
Yogurt Study in Children 2-4 Years Old Attending Daycare
NCT00760851
Group Intervention for Interpersonal Trauma
NCT00348036
Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)
NCT00810368
Study of Gulf War Illness (GWI) by Comparing GWI and Healthy Veterans
NCT00810225
A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT
NCT00727597
Preventing Recurrence of Thromboembolic Events Through Coordinated Treatment in the District of Columbia
NCT00703274
Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy
NCT00661531
Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children
NCT00685256
A Prospective Study of Autologous Fat Grafting for Breast Augmentation
NCT00663156
Acute Stroke Program of Interventions Addressing Racial and Ethnic Disparities
NCT00724555
Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
NCT00860457
Registry of Mastectomy for Breast Cancer Risk Reduction
NCT00555503
Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
NCT00509067
Internet-Based Education for Prostate Cancer Screening
NCT00623090
Study of Pemetrexed for Second-Line Pancreas Cancer
NCT00864513
Study to Investigate the Potential of Probiotics in Yogurt
NCT00492583
Measuring the Influence of Kefir on Children's Stools on Antibiotics (MILK)
NCT00481507
Proteomics of Cerebrospinal Fluid in Chronic Fatigue Syndrome
NCT00810329
A Physician-Based Trial to Increase Colorectal Cancer Screening in Chinese
NCT01289288
African American Knowledge Optimized for Mindfully Healthy Adolescents
NCT00578318
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 43 |
| Phase 2 | 55 |
| Phase 3 | 16 |
| Phase 4 | 11 |
Therapeutic Areas
What is open in the Georgetown University pipeline
34 recruiting of 227 indexed (15% open); 130 completed (57%).
Phase mix: 27 late (III/IV) vs 98 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Georgetown University: open-pipeline peers nationwide
Peers matched on 227 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Georgetown University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 227 trials (± recruiting share)
- University of Iowa · 228 trials · 12% recruiting
- University Hospitals Cleveland Medical Center · 230 trials · 18% recruiting
- Brown University · 231 trials · 15% recruiting
- National Eye Institute (NEI) · 221 trials · 8% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Arizona State University · 15% recruiting · 187 trials
- 59th Medical Wing · 15% recruiting · 20 trials
- Alliance Foundation Trials · 15% recruiting · 20 trials
- Hoag Memorial Hospital Presbyterian · 15% recruiting · 20 trials
Related
What to do with this Georgetown University page
227 registered trials is a research-attention snapshot, not an endorsement of Georgetown University or any single study.
- 34 of Georgetown University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Georgetown University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Georgetown University pipeline card: 227 registered trials from official public datasets.Report a data error.